Strekin announces the closing of a CHF2.82m Series A financing

– SWITZERLAND, Basel –  Strekin AG, a Basel, Switzerland-based clinical-stage biopharmaceutical company, closed a CHF2.82M Series A financing from new and existing investors.

The company intends to use the funds to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss, the RESTORE trial, and to prepare for a European filing.

About Strekin

Strekin AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland. Strekin was founded in 2014 by Dr. Alexander Bausch, Prof. Dr. Daniel Bodmer, and Mr. Roger Meier.

For more, visit

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.